Cancers Local recurrence after surgery is a primary limitation for cure in patients with biliary tract cancers, which provides an important justification for the use of adjuvant therapy. Nevertheless, the role of adjuvant chemotherapy or chemoradiation
Search Results
Al B. Benson III, Michael I. D’Angelica, Thomas A. Abrams, Chandrakanth Are, P. Mark Bloomston, Daniel T. Chang, Bryan M. Clary, Anne M. Covey, William D. Ensminger, Renuka Iyer, R. Kate Kelley, David Linehan, Mokenge P. Malafa, Steven G. Meranze, James O. Park, Timothy Pawlik, James A. Posey, Courtney Scaife, Tracey Schefter, Elin R. Sigurdson, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Yun Yen, Andrew X. Zhu, Karin G. Hoffmann, Nicole R. McMillian, and Hema Sundar
Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia
counterparts, which might be due to aggressive tumor biology and lower efficacy of adjuvant therapy, including endocrine therapy for HR-positive breast cancer in young women. For example, among patients with HR-positive disease, there are data in a Korean
Rahel Demisse, Neha Damle, Edward Kim, Jun Gong, Marwan Fakih, Cathy Eng, Leslie Oesterich, Madison McKenny, Jingran Ji, James Liu, Ryan Louie, Kit Tam, Sepideh Gholami, Wissam Halabi, Arta Monjazeb, Farshid Dayyani, and May Cho
fluorouracil-based adjuvant therapy in colon cancer . J Clin Oncol 2010 ; 28 : 3219 – 3226 . 20498393 10.1200/JCO.2009.27.1825 13. Salem ME , Hartley M , Unger K , . Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar
these with patients and families and pick the best approach on a case-by-case basis. Adjuvant Therapy: Oliver et al 35 reported on the results of a trial that randomized 1477 patients with stage 1 testicular cancer to undergo either radiotherapy or
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
: Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. Some data support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on nonuniform panel consensus. A phase II trial of temozolomide
Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin
guidelines, visit NCCN.org . 2. Macdonald OK Crane CH . Palliative and postoperative radiotherapy in biliary tract cancer . Surg Oncol Clin N Am 2002 ; 11 : 941 – 954 . 3. Hoehn RS Wima K Ertel AE . Adjuvant therapy for
Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard, and Charles L. Loprinzi
across the world, including an adjuvant therapy trial (N04C7) that had accrued approximately 100 patients. However, a subsequent review of the data monitoring committee report showed that it was aberrant, and a subsequent Letter to the Editor in JCO
Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy
-free survival, there was clear benefit for nivolumab as adjuvant therapy (22.4 vs 11.0 months; HR, 0.69; P =.0003), with the benefit sustained over time. Nivolumab was favored in all subgroups. “This is the most robust data we have seen showing any benefit
Presenters: Dara L. Aisner and Gregory J. Riely
NCCN Guidelines now list osimertinib as an option for adjuvant therapy in patients with resectable stage IIB–IIIA or high-risk stage IB–IIA NSCLC harboring EGFR mutations who received previous adjuvant chemotherapy or are ineligible to receive
Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook
tumor specimens of patients enrolled in randomized studies of adjuvant 5-fluorouracil with levamisole or leucovorin compared with no adjuvant therapy. 98 This study showed no improvement in overall survival in patients with stage II and III colon cancer
